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Abstract: Cytological specimens from computed tomography (CT)-guided needle aspiration biopsy (CT-NAB) have 
relatively low sensitivity for lung cancer diagnosis. This study evaluated the usefulness of the dual immunofluores-
cence (IF) staining method using methionyl-tRNA synthetase (MARS), aminoacyl-tRNA synthetases interacting multi-
functional protein-lacking exon 2 (AIMP2-DX2), and pan-cytokeratin (pan-CK) obtained from clinical specimens. 
One-hundred forty-five cytology specimens were prospectively collected from patients who underwent CT-NAB under 
the suspicion of lung cancer. The results of two combinations of MARS, AIMP2-DX2, and pan-CK dual IF staining 
were compared with those of conventional cytology by calculating the area under the curve (AUC). The results of 
combining dual IF with conventional cytology showed higher AUC than conventional cytology alone: cytology/MARS/
AIMP2-DX2 (0.891 vs. 0.829, P = 0.003), cytology/MARS/pan-CK (0.916 vs. 0.829, P < 0.001), and cytology/
AIMP2-DX2/pan-CK (0.877 vs. 0.829, P = 0.005). In specimens with non-diagnostic results in conventional cytology, 
MARS/AIMP2-DX2 dual IF staining showed sensitivity, specificity, and AUC of 60.0%, 86.4%, and 0.79, respectively. 
The dual IF staining method using two combinations of MARS, AIMP2-DX2, and pan-CK is an effective diagnostic 
tool that can improve the lung cancer diagnostic yield by complementing conventional cytology.
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Introduction
CT-guided needle aspiration biopsy (CT-NAB) is 
a commonly used standard method for the 
pathologic diagnosis of pulmonary nodules. 
However, cytological specimens obtained by 
CT-NAB have a relatively low sensitivity of 
56.3%-86.5% [1]. In a previous study, the non-
diagnostic rate of CT-NAB was 27.6%, of which 
40.4% of patients were finally diagnosed with 
lung cancer [2]. Factors associated with non-
diagnostic results in CT-NAB include smaller 
lesion size (≤ 15 mm), needle penetrating the 
emphysema, and introducer needle located 
outside the lesion [3]. In this case, an insuffi-
cient volume of specimen is obtained, and th- 
us vague expressions such as “suspicious for 
malignancy”, “atypical cells”, and “cellular pau-
city” are often used in conventional cytology 
results. When a non-diagnostic result is ob- 
tained, patients must undergo re-biopsy throu- 
gh additional procedures or surgery, and treat-
ment decisions are inevitably delayed. 
Currently, immunohistochemical staining mark-
ers used to diagnose lung cancer include thy-
roid transcription factor-1 (TTF-1) and napsin A 
for adenocarcinoma, and p40, p63, and cyto-
keratin 5/6 for squamous cell carcinoma [4]. 
However, these markers are not specific for 
lung cancer; TTF-1 and napsin A are useful 
markers for determining cell origin, while p63 
and cytokeratin 5 are markers for squamous 
cell carcinoma [5-9]. In addition, these markers 
are difficult to apply to NAB-derived samples. 
Because it is difficult to obtain sufficient speci-
mens, non-specific staining patterns, such as 
an edge effect (adsorption), may be observed. 
To overcome these problems, we developed a 
new staining method and markers applicable to 
cytological specimens.
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Aminoacyl-tRNA synthetases (ARSs) are a gr- 
oup of enzymes that play important roles in pro-
tein synthesis by charging tRNA with their cog-
nate amino acids [10]. Methionyl-tRNA synthe-
tase (MARS), one of the ARSs, plays an essen-
tial role in the initiation of translation by ligating 
methionine to tRNA [11]. In addition, MARS is 
overexpressed in lung cancer, and its overex-
pression is associated with poor clinical out-
comes in lung cancer patients [12]. ARS exists 
in a complex-bound form called the multi-tRNA 
synthetase complex (MSC), which includes 
three ARS-interacting multifunctional proteins 
(AIMPs), named AIMP1, AIMP2, and AIMP3. 
AIMP2 not only functions as a simple scaffold-
ing protein in MSCs, but also participates in 
lung epithelial cell differentiation [13]. An alter-
native splicing variant of AIMP2 lacking exon 2 
(AIMP2-DX2) has been reported to be highly 
expressed in human lung cancer and is associ-
ated with poor prognosis in lung cancer patients 
[14, 15]. Pan-cytokeratin (pan-CK) is expressed 
in all epithelial cells and is a useful marker of 
epithelial origin cells [16, 17]. Pulmonary nod-
ules consist of lung cancer cells, which origi-
nate from epithelial cells and fibroblasts, neo-
vascular tissues and inflammatory cells, which 
originate from mesenchymal cells. Therefore, 
pan-CK can help distinguish mesenchymal ori-
gin cells from epithelial origin lung cancer cells.
The purpose of this study was to evaluate the 
diagnostic value of two combinations of MARS, 
AIMP2-DX2, and pan-CK in cytology specimens 
obtained by CT-NAB. We evaluated whether 
the immunofluorescence (IF) staining method 
of these candidates could be applied to rapid 
on-site examination (ROSE) for lung cancer 
diagnosis. 
Materials and methods
Study design and subjects 
To evaluate AIMP2-DX2 expression in mouse 
lung cancer, we performed immunoblot and 
immunohistochemistry (IHC) analyses using ti- 
ssue lysates and paraffin-embedded tissue 
blocks from wild-type C57BL/6, LSL-Kras 
G12D, and LSL-Kras G12D: p53fl/fl mice. To 
prepare mouse lung cancer tissue, LSL-Kras 
G12D and LSL-Kras G12D: p53fl/fl mice inhaled 
AdCre particles at 8 weeks and were sacrific- 
ed at 24 weeks after inhalation (http://mouse.
ncifcrf.gov/). All animal studies were approved 
by the Institutional Animal Care and Use 
Committee of Yonsei University (2014-0229-1) 
according to the guidelines of the American 
Association for the Assessment and Accredi- 
tation of Laboratory Animal Care. To evaluate 
AIMP2-DX2 expression in human lung cancer, 
specimens were prospectively collected from 
patients who (1) visited Gangnam Severance 
Hospital, affiliated with Yonsei University, (2) 
had a significant lung nodule (greater than 1.0 
cm in diameter) on contrast-enhanced CT, and 
(3) underwent CT-NAB. Residual tissues and 
cytologic specimens were used after pathologi-
cal examinations obtained from CT-NAB. A total 
of 175 formalin-fixed paraffin-embedded lung 
cancer tissue slides were analyzed by IHC, and 
145 cytological specimens were analyzed by 
immunofluorescence staining. This study was 
approved by the Institutional Review Board of 
Gangnam Severance Hospital (approval no. 
3-2014-0299 and 3-2018-0009) and was car-
ried out in compliance with the Declaration 
of Helsinki, and all patients provided written 
informed consent. 
Antibodies, cells, and other materials
Anti-MARS mouse antibodies (EPR9873(B)) 
from Oncotag® (#HFTAG201, Suwon, Kyung-
kido, Korea), AIMP2-DX2 rabbit antibodies fr- 
om Biocon® (Suwon, Kyungkido, Korea), cyto-
keratin AE1 + AE3 antibodies from LifeSpan 
BioSciences Inc. (#LS-C357999, WA, USA), 
and pan-CK (KRT777) rabbit antibodies from 
MyBioSource (#MSB4380427, CA, USA) were 
used in this study. Molt-4, Daudi, and H460 
cells were obtained from the Korean Cell Line 
Bank (Seoul, Korea). ThinPrep PreservCyt® so- 
lution was obtained from Hologic Inc. (#70097-
002, Marlborough, MA, USA) and the Envision 
Kit and DAB from Dako (#K3468, Carpinteria, 
CA, USA).
Immunoblotting
Mouse tissues were harvested using 2× LSB 
lysis buffer containing protease and phospha-
tase inhibitors (GenDepo, Korea) on ice. After 
homogenization and sonication, 30-50 mg of 
lysates was separated by gel electrophoresis 
on 7.5%-12% polyacrylamide gels and trans-
ferred onto nitrocellulose membranes (Bio- 
Rad Laboratories, Inc., Richmond, CA, USA). 
The expression level of each protein was mea-
sured using ImageJ (http://rsbweb.nih.gov/ij/) 
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and quantified relative to that of β-actin (Figure 
1D).
Immunohistochemistry (IHC)
AIMP2-DX2 expression was analyzed by IHC 
using the LABS®2 System (Dako, Carpinteria, 
CA, USA) in mouse lung tissue and human lung 
cancer tissue. Specimen sections were depar-
affinized, rehydrated, immersed in H2O2 metha-
nol solution, and then incubated overnight 
with primary antibodies against AIMP2-DX2 
obtained by rabbit immunization at a 1:2000 
dilution. Sections were incubated for 10 min 
with a biotinylated linker and processed using 
avidin/biotin IHC techniques. 3,3-Diaminoben- 
zidine (DAB) was used as a chromogen in con-
junction with the Liquid DAB Substrate kit 
(Novacastra, UK). 
Immunofluorescence (IF) staining
Thinprep slides were immersed in 1X PBS for 5 
min and then permeabilized with 0.2% PBS-T 
for 30 min at room temperature. After washing 
with 1X PBS, the sections were blopan-cytoker-
atined with 2% goat serum for 1 h and then 
incubated with primary antibody mixtures pre-
pared in PBS for 90 min. Three combinations of 
primary antibody mixtures were as follows: (1) 
MARS diluted at a ratio of 1:250 and pan-CK 
diluted at a ratio of 1:200, (2) AIMP2-DX2 dilut-
ed at a ratio of 1:200, and pan-CK diluted at a 
ratio of 1:200; and (3) MARS diluted at a ratio 
of 1:250 and AIMP2-DX2 diluted at a ratio of 
1:200. After washing, the sections were incu-
bated with 1:1000 diluted secondary antibody 
mixture containing anti-rabbit-AF488 and anti-
mouse-AF555 at room temperature for 1 h and 
then allowed to react with 4’, 6-Diamidine-2’-
phenylindole dihydrochloride (DAPI) for 1 min to 
counterstain the nuclei. The slides were mount-
ed with coverslips using ProLong Gold Antifade 
Reagent® (P36930, Invitrogen, Carlsbad, CA, 
USA), and the slides were shaded and stored 
frozen at -20°C. Stained slides were observed 
using a Carl-Zeiss Imager M2 fluorescence 
Figure 1. Expression of AIMP2-DX2 in mouse and human lung tissue by immunoblotting and immunohistochemistry. 
A. Immunoblot analysis of AIMP2-DX2 expression in wild type C57BL/6 mice, LSL-Kras G12D and LSL-Kras G12D: 
p53fl/fl lung cancer model mice. B. Lung cancer progression and AIMP2-DX2 expression in LSL-Kras G12D mouse 
model over time. C. Normal-appearing mouse tissues adjacent to lung cancer tissues in LSL-Kras G12D and LSL-
Kras G12D: p53fl/fl lung cancer model mice. D. Distribution of cytoplasmic and nuclear expression of AIMP2-DX2 in 
175 human lung cancer cases as assessed by immunohistochemistry. 
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microscope (Imager M2, Carl Zeiss, Oberkochen, 
Germany), and images were analyzed using 
ZEN-lite software (Carl Zeiss).
Interpretation criteria and statistical analysis
The following four criteria were applied for the 
classification of cells as non-small cell lung 
cancer (NSCLC): (1) a nucleus diameter ≥ 10 
μm; (2) no identification in the nucleus; (3) 
prominent nucleoli; and (4) MARS positivity, 
AIMP2-DX2 positivity, and pan-CK positivity. 
The MARS, AIMP2-DX2, and pan-CK staining 
results of clinical specimens were interpreted 
by comparing the staining intensity of the re- 
ference sample. Two independent researchers 
(K-L and T-K) who were blinded to the patholo- 
gical reports analyzed the slides; in case of dis-
crepancy in the results between the two inves-
tigators, a third researcher (YS-C) also evaluat-
ed the slides. The area under the curve (AUC) 
was calculated and compared using the De- 
Long’s method. The optimal cutoff point for 
separating the smaller nodule group from the 
larger nodule group was determined by the 
receiver operating characteristic (ROC) curve 
using the Youden index. Kappa (κ) statistics 
were used to evaluate the interobserver agr- 
eement among the pathologist and author’s 
NSCLC diagnoses.
Results
AIMP2-DX2 were highly expressed in NSCLC 
tissue
To evaluate AIMP2-DX2 as a lung cancer-specif-
ic biomarker, its expression was estimated in 
Kras-LSL G12D and Kras-LSL G12: p53fl/fl lung 
cancer models and human lung cancer tissues. 
In mouse model, overexpression of AIMP2-DX2 
showed in lung cancer than normal lung tiss- 
ue by immunoblotting (Figure 1A). In addition, 
AIMP2-DX2 was highly expressed in lung can-
cer tissue than normal-appearing tissues adja-
cent to lung cancer (Figure 1B). To evaluate the 
AIMP2-DX2 expression in human lung cancer, 
we investigated 175 paraffin-embedded NSCLC 
tissue samples. AIMP2-DX2 expression was 
scored as follows: product of intensity and 
frequency, score 0-2: negative/trace AIMP2-
DX2 expression; score more than 3: positive 
AIMP2-DX2 expression. One hundred sixty-five 
(94.3%) cases had positive AIMP2-DX2 cyto-
plasmic expression (Figure 1C) and showed its 
strong expression in NSCLC specimens (Figure 
1D). Kim et al. reported that MARS was over- 
expressed in NSCLC tissue samples and was 
associated with shorter disease-free survival 
in patients with NSCLC [12]. Jung et al. docu-
mented that AIMP2-DX2 was detected in 58.3% 
of blood samples collected from lung cancer 
cases, which was related to poor clinical out-
comes [18]. Taken these results together, it 
showed that both MARS and AIMP2-DX2 were 
specifically overexpressed in lung cancer.
Clinicopathological characteristics of study 
cases 
Two hundred seven cytology specimens were 
prospectively collected during CT-NAB, and 145 
specimens were prepared with Thinprep slides 
(Figure 2). The clinical characteristics of the 
Figure 2. Diagram of study 
design. * The clinical di-
agnosis of negative malig-
nancy was defined when 
the lesion size did not 
change, decreased, or dis-
appeared when observed 
for more than 6 months.
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enrolled patients are shown in Table 1. The 
mean age of the study population was 67.4 ± 
11.0 years, and 94 (64.8%) were male. In 122 
patients, the diagnosis was confirmed by pa- 
thological examination. For the remaining 23 
patients, diagnosis was made based on find-
ings from imaging studies performed during a 
clinical follow-up for at least 6 months. In the 
final diagnosis, 79 cases (54.5%) were adeno-
carcinoma and 18 cases (12.4%) were squa-
mous cell carcinoma, whereas 34 cases 
(23.4%) were confirmed as benign pulmonary 
nodules. 
Conventional cytology versus two combina-
tions of MARS/AIMP2-DX2/pan-CK dual IF 
staining
In the reference sample, comprised of H460, 
Daudi, and Molt-4 cells at fixed ratio of 1:1:1, 
MARS/AIMP2-DX2 dual IF showed dual positive 
colocalization (orange) in most cells. In combi-
nations of MARS/pan-CK and AIMP2-DX2/pan-
CK, dual IF results showed dual positive colo-
calization (orange) according to the proportion 
of H460 cell lines (Figure 3A). However, colo- 
calization of the two substances was not al- 
ways present, and some cells were seen as red 
and green color separately. 
In clinical specimens, NSCLC cells were defined 
by the presence of dual positive colocalization 
(orange color) signal in the cytosol (Figure 3B), 
and benign specimens presented no dual IF 
staining (Figure 3D). Figure 3C and 3E repre-
sent the results of conventional cytology 
in NSCLC case (same specimen provided in 
Figure 1B) and benign case (same specimen 
provided in Figure 1D), respectively. Of the 
collected 145 specimens, 47 were diagnosed 
with benign disease and 98 were diagnosed 
with NSCLC. Of the 98 cases diagnosed with 
NSCLC, the positive rate of the conventional 
cytology result was 75 cases (76.5%). The 
proportion of dual IF staining was 76 cases 
(77.6%) for MARS/AIMP2-DX2, MARS/pan-CK, 
and 78 cases (79.6%) for AIMP2-DX2/Pan-CK 
(Table 2). In all combinations of these three 
markers, the staining percentage of co-locali- 
zation in the NSCLC specimen were reported 
higher than those of the benign specimens 
(14.9% vs 77.6% in MARS/AIMP2-DX2, 17.0% 
vs. 77.6% in MARS/pan-CK, and 25.5% vs. 
78.6% in AIMP2-DX2/Pan-CK, Figure 3F).
In addition, we compared the diagnostic yield 
of conventional cytology with MARS/AIMP2-
DX2, MARS/pan-CK, and AIMP2-DX2/pan-CK 
dual IF staining (Table 3). The sensitivity of 
conventional cytology using pap staining was 
76.5%, specificity was 89.4%, and AUC was 
0.829. On the other hand, those of dual IF of 
MARS/AIMP2-DX2 were 81.4%, 87.2%, and 
0.863, respectively, which tended to increase 
sensitivity and AUC compared to those of 
conventional cytology. Those of MARS/pan-CK 
dual IF were 74.5%, 87.2%, and 0.829, respec-
tively, and the AUC was equivalent to that of 
conventional cytology. Those of AIMP2-DX2/
pan-CK were 82.7%, 74.5%, and 0.814, respec-
tively, which tended to increase sensitivity com-
pared to that of conventional cytology. How- 
ever, when comparing the ROC curves of the 
cytology and dual IF staining results, the differ-
ence was not significant (Figure 4A).
Conventional cytology versus combinations of 
dual IF staining with cytology
In addition, we compared the diagnostic yield 
when combined with the results of cytology and 
dual IF staining. The sensitivity of cytology com-
bined with MARS/AIMP2-DX2 was 86.7%, and 
specificity was 85.1%, and AUC was 0.891, 
which showed significantly increased sensitivi-
ty and AUC compared to those of conventional 
cytology (DeLong’s method, cytology vs. cytol-
ogy/MARS/AIMP2-DX2: P = 0.003). For the 
combination of cytology and MARS/pan-CK 
Table 1. Characteristics of patients from 
whom CT-guided needle aspiration cytology 
specimens were collected (n = 145)
Characteristics Value
Mean age (years) 67.4 ± 11.0
Gender
    Male 94 (64.8)
    Female 51 (35.2)
Mean diameter of primary lesion (cm) 3.69 ± 1.93
Final diagnosis
    Benign 34 (23.4)
    Adenocarcinoma 79 (54.5)
Squamous cell carcinoma 18 (12.4)
Small cell lung cancer 3 (2.1)
Lung cancer, unspecified 3 (2.1)
Metastatic cancer from other organs 8 (5.5)
Values are n (%) unless otherwise defined.
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dual IF, sensitivity was 74.5%, specificity was 
85.7%, and AUC was 0.916, showing a signifi-
cantly higher specificity and AUC compared to 
those of other results (DeLong’s method, cy- 
tology vs. cytology/MARS/pan-CK: P < 0.001). 
When combining the results of cytology and 
AIMP2-DX2/pan-CK dual IF, the sensitivity was 
77.6%, specificity was 89.4%, and AUC was 
0.877, which showed significantly increased 
sensitivity and AUC compared to those of con-
ventional cytology (DeLong’s method, cytology 
vs. cytology/AIMP2-DX2/pan-CK: P = 0.005). 
The results of comparing ROC curves are pre-
sented in Figure 4B. 
Comparison of the diagnostic yields from non-
diagnostic result in conventional cytology
Among the 42 patients with specimens that 
reported atypical cells or suspicious findings for 
Figure 3. IF staining images of MARS, AIMP2-DX2, and pan-CK. (A) IF staining for MARS/AIMP2-DX2, MARS/pan-CK, 
and AIMP2-DX2/pan-CK in reference samples comprised of H460, Daudi, and Molt-4 cells at a fixed ratio of 1:1:1. 
(B) Dual IF staining images of MARS/AIMP2-DX2, MARS/pan-CK, AIMP2-DX2/pan-CK, and (C) image of conventional 
cytology in the CT-NAB-derived sample (final diagnosis: NSCLC). (D) Dual IF staining images of MARS/AIMP2-DX2, 
MARS/pan-CK, AIMP2-DX2/pan-CK, and (E) image of conventional cytology in the CT-NAB-derived sample (final 
diagnosis: benign disease). Images were taken using a Carl-Zeiss Imager M2 fluorescence microscope. (F) Staining 
percentages of MARS, AIMP2-DX2, pan-CK, and co-localization in the benign and NSCLC specimens.
Table 2. Comparison of the results in conventional cytology versus dual IF staining
Clinicopathologic 
diagnosis
Conventional cytology MARS/AIMP2-DX2 dual IF MARS/pan-CK dual IF AIMP-DX2/pan-CK dual IF
positive negative positive negative positive negative positive negative
Malignancy 75 23 76 22 76 22 78 20
Benign 5 42 7 40 8 39 12 35
MARS, methionyl-tRNA synthetase; AIMP2, aminoacyl-tRNA synthetase interacting multifunctional protein 2; pan-CK, pan-cytokeratin; IF, immuno-
fluorescence.
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malignancy by conventional cytology, the final 
clinicopathological analysis revealed 20 malig-
nancies and 22 benign lesions. Among the 20 
malignancies, 13 were positive and 7 were neg-
ative according to the MARS/AIMP2-DX2 dual 
IF staining (Table 4). Cytologic diagnosis that 
was indeterminate by conventional cytology 
was markedly improved by MARS/AIMP2-DX2 
dual IF staining. The sensitivity, specificity, and 
AUC were 60.0%, 86.4%, and 0.790, respec-
tively (Table 5; Figure 4C).
Discussion
In this study, lung cancer diagnosis using dual 
IF staining combinations of MARS and AIMP2-
DX2 as lung cancer-specific markers, and pan-
CK as an epithelial cell marker, showed good 
diagnostic performance. When our dual IF st- 
aining was combined with the conventional 
cytology results, all three combinations, MARS/
AIMP2-DX2, MARS/pan-CK, and AIMP2-DX2/
pan-CK, showed superior diagnostic yield than 
cytology alone. Moreover, the MARS/AIMP2-
DX2 dual IF staining had good diagnostic pow- 
er for specimens with non-diagnostic cytology 
results (sensitivity, 60.0%; specificity, 86.4%; 
AUC, 0.79). Therefore, the application of MARS/
AIMP2-DX2 dual IF can improve the diagnostic 
yield of undiagnosed specimens using conven-
tional cytology.
Table 3. Comparison of diagnostic yields in conventional cytology versus dual IF staining
Sensitivity (%) Specificity (%) AUC p-value
Conventional cytology 76.5 89.4 0.829
MARS/AIMP2-DX2 dual IF 81.6 87.2 0.863 0.456*
MARS/pan-CK dual IF 74.5 87.2 0.829 0.984*
AIMP-DX2/pan-CK dual IF 82.7 74.5 0.814 0.643*
Cytology + MARS/AIMP2-DX2 dual IF 86.7 85.1 0.891 0.003†
Cytology + MARS/pan-CK dual IF 74.5 95.7 0.916 <0.001†
Cytology + AIMP-DX2/pan-CK dual IF 77.6 89.4 0.877 0.005†
AUC, area under the curve; MARS, methionyl-tRNA synthetase; AIMP2, aminoacyl-tRNA synthetase interacting multifunctional 
protein 2; pan-CK, pan-cytokeratin; IF, immunofluorescence. *DeLong’s method, cytology vs. dual IF results, †DeLong’s method, 
cytology vs. cytology + dual IF results.
Figure 4. ROC curve analysis of the diagnostic value for lung cancer. (A) ROC curves of conventional cytology versus 
dual IF staining. (B) ROC curves of conventional cytology versus combination of cytology with dual IF staining. (C) 
ROC curves of IF staining in non-diagnostic cytology result (C). 
Table 4. Comparison of results from non-diagnostic result in conventional cytology
Clinicopathologic diagnosis
MARS/AIMP2-DX2 dual IF MARS/pan-CK dual IF AIMP-DX2/pan-CK dual IF
positive negative positive negative positive negative
Malignancy 13 7 8 12 9 11
Benign 2 20 15 7 6 16
MARS, methionyl-tRNA synthetase; AIMP2, aminoacyl-tRNA synthetase interacting multifunctional protein 2; pan-CK, pan-
cytokeratin; IF, immunofluorescence.
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In our study, there was no significant difference 
in the results when comparing the ROC curves 
of dual IF staining with those of conventional 
cytology for lung cancer diagnosis. Therefore, 
we additionally evaluated the agreement be- 
tween conventional cytology and dual IF stain-
ing using Cohen’s kappa. There was a substan-
tial agreement between conventional cytology 
and dual IF staining (κ = 0.71 for cytology vs. 
MARS/AIMP2-DX2, κ = 0.64 for cytology vs. 
MARS/pan-CK, and κ = 0.62 for cytology vs. 
AIMP2-DX2/pan-CK). The reason for the dis-
agreement between the two test results was 
that pathologists tended to judge conservative-
ly, while dual IF staining was judged blinded to 
the patients’ clinical information. Because the 
two test results did not match, the dual IF stain-
ing method could be used as a complementary 
diagnostic method.
ROSE provides real-time feedback on informa-
tion about the quantity and quality of needle 
aspiration samples. Several studies reported 
that the application of ROSE increased the 
diagnostic yield, decreased the complication 
rate by reducing the number of needle penetra-
tions, and reduced costs by avoiding additional 
diagnostic procedures [19-21]. However, ROSE 
is difficult to apply in clinical practice because 
it can be time-consuming and costly since it 
requires a cytopathologist to be present at the 
examination site [22]. Recently, telecytology 
has emerged as a cost-effective and time-
effective method for ROSE. When rapid assess-
ment was performed using telecytology on 
specimens from small biopsies, the diagnostic 
yield was increased and the proportion of non-
diagnostic specimens decreased by 3% [23, 
24]. In the present study, the lung cancer-spe-
cific MARS and AIMP2-DX2 dual IF staining 
method was able to derive diagnostic results 
simply and intuitively; hence, it could be candi-
date biomarkers for ROSE using telecytology.
CT-NAB was performed only when lung malig-
nancy was suspected in the imaging study. 
Third, liquid-based cytology slides (Thinprep) 
were used in this study for MARS and AIMP2-
DX2 IF staining, whereas direct smear staining 
was used in conventional cytology specimens. 
Further large-scale prospective studies are re- 
quired to determine whether there are differ-
ences in dual IF staining between liquid-based 
cytology slides and direct smears. 
In conclusion, the accuracy of the diagnosis of 
pulmonary nodules is critical for patient’s treat-
ment decisions. The results of combined cytol-
ogy and two combinations of dual IF staining 
using MARS, AIMP2-DX2, and pan-CK showed 
improved diagnostic yield compared to con- 
ventional cytology alone. Moreover, the MARS/
AIMP2-DX2 dual IF staining showed good diag-
nostic performance for specimens with non-
diagnostic cytology results. Therefore, IF stain-
ing using ARSs could be a specific and comple-
mentary diagnostic method for lung cancer. 
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